COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, ...

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

G&A Expenses: For the quarter ended September 30, 2024, general and administrative (G&A) expenses were $4.4 million, compared to $5.0 million for the same period in 2023. The decrease was primarily ...

Australia: A recent study published in Clinical Infectious Diseases has shown that the current use of integrase strand ...

The pilot open-label randomized clinical trial demonstrated that the use of the drug in addition to protease inhibitor ...

Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.

The following are highlights of the Company's 2024 third quarter results: Sales in the third quarter grew to $8,435,178, compared to $5,957,668 during the same period last year, an increase of 42%.

Netherton syndrome (NS), a rare genetic skin disorder resulting from serine protease inhibitor Kazal type 5 (SPINK5) gene ...

Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments. Researchers conducted a ...